Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes - PubMed (original) (raw)
Clinical Trial
. 2004 Nov;27(11):2628-35.
doi: 10.2337/diacare.27.11.2628.
Affiliations
- PMID: 15504997
- DOI: 10.2337/diacare.27.11.2628
Clinical Trial
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes
John B Buse et al. Diabetes Care. 2004 Nov.
Abstract
Objective: This study evaluated the ability of the incretin mimetic exenatide (exendin-4) to improve glycemic control in patients with type 2 diabetes failing maximally effective doses of a sulfonylurea as monotherapy.
Research design and methods: This was a triple-blind, placebo-controlled, 30-week study conducted at 101 sites in the U.S. After a 4-week, single-blind, placebo lead-in period, 377 subjects were randomized (60% men, age 55 +/- 11 years, BMI 33 +/- 6 kg/m(2), HbA(1c) 8.6 +/- 1.2% [+/-SD]) and began 4 weeks at 5 microg subcutaneous exenatide twice daily (before breakfast and dinner; arms A and B) or placebo. Subsequently, subjects in arm B were escalated to 10 microg b.i.d. exenatide. All subjects continued sulfonylurea therapy.
Results: At week 30, HbA(1c) changes from baseline were -0.86 +/- 0.11, -0.46 +/- 0.12, and 0.12 +/- 0.09% (+/-SE) in the 10-microg, 5-microg, and placebo arms, respectively (adjusted P < 0.001). Of evaluable subjects with baseline HbA(1c) > 7% (n = 237), 41% (10 microg), 33% (5 microg), and 9% (placebo) achieved HbA(1c) <or= 7% (P < 0.001). Fasting plasma glucose concentrations decreased in the 10-microg arm compared with placebo (P < 0.05). Subjects in the exenatide arms had dose-dependent progressive weight loss, with an end-of-study loss in the 10-microg exenatide arm of -1.6 +/- 0.3 kg from baseline (P < 0.05 vs. placebo). The most frequent adverse events were generally mild or moderate and gastrointestinal in nature. No severe hypoglycemia was observed.
Conclusions: Exenatide significantly reduced HbA(1c) in patients with type 2 diabetes failing maximally effective doses of a sulfonylurea. Exenatide was generally well tolerated and was associated with weight loss.
Similar articles
- Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.
DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. DeFronzo RA, et al. Diabetes Care. 2005 May;28(5):1092-100. doi: 10.2337/diacare.28.5.1092. Diabetes Care. 2005. PMID: 15855572 Clinical Trial. - Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea.
Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, Baron AD. Kendall DM, et al. Diabetes Care. 2005 May;28(5):1083-91. doi: 10.2337/diacare.28.5.1083. Diabetes Care. 2005. PMID: 15855571 Clinical Trial. - Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.
Moretto TJ, Milton DR, Ridge TD, Macconell LA, Okerson T, Wolka AM, Brodows RG. Moretto TJ, et al. Clin Ther. 2008 Aug;30(8):1448-60. doi: 10.1016/j.clinthera.2008.08.006. Clin Ther. 2008. PMID: 18803987 Clinical Trial. - Exenatide: an incretin mimetic for the treatment of type 2 diabetes mellitus.
Iltz JL, Baker DE, Setter SM, Keith Campbell R. Iltz JL, et al. Clin Ther. 2006 May;28(5):652-65. doi: 10.1016/j.clinthera.2006.05.006. Clin Ther. 2006. PMID: 16861088 Review. - Metabolic effects of the incretin mimetic exenatide in the treatment of type 2 diabetes.
Schnabel CA, Wintle M, Kolterman O. Schnabel CA, et al. Vasc Health Risk Manag. 2006;2(1):69-77. doi: 10.2147/vhrm.2006.2.1.69. Vasc Health Risk Manag. 2006. PMID: 17319471 Free PMC article. Review.
Cited by
- Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals.
Meloni AR, DeYoung MB, Han J, Best JH, Grimm M. Meloni AR, et al. Cardiovasc Diabetol. 2013 Mar 23;12:48. doi: 10.1186/1475-2840-12-48. Cardiovasc Diabetol. 2013. PMID: 23522121 Free PMC article. Clinical Trial. - Optimal Pharmacologic Treatment Strategies in Obesity and Type 2 Diabetes.
Goswami G, Shinkazh N, Davis N. Goswami G, et al. J Clin Med. 2014 Jun 18;3(2):595-613. doi: 10.3390/jcm3020595. J Clin Med. 2014. PMID: 26237392 Free PMC article. Review. - Exenatide Use in the Management of Type 2 Diabetes Mellitus.
Kyriacou A, Ahmed AB. Kyriacou A, et al. Pharmaceuticals (Basel). 2010 Aug 11;3(8):2554-2567. doi: 10.3390/ph3082554. Pharmaceuticals (Basel). 2010. PMID: 27713366 Free PMC article. Review. - GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus.
Meier JJ. Meier JJ. Nat Rev Endocrinol. 2012 Dec;8(12):728-42. doi: 10.1038/nrendo.2012.140. Epub 2012 Sep 4. Nat Rev Endocrinol. 2012. PMID: 22945360 Review. - Utilizing the GLP-1 signaling system to treat diabetes: sorting through the pharmacologic approaches.
D'Alessio DA, Vahl TP. D'Alessio DA, et al. Curr Diab Rep. 2005 Oct;5(5):346-52. doi: 10.1007/s11892-005-0092-2. Curr Diab Rep. 2005. PMID: 16188169 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous